X4 Pharmaceuticals (XFOR) Tops Q2 EPS by 6c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of ($0.13), $0.06 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $8.81 million versus the consensus estimate of $2.28 million.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Copart (CPRT) Misses Q4 EPS by 4c
• RH shares jump after second quarter beat